These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38270600)

  • 1. Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.
    Sobue Y; Nishi K; Kamei K; Inoki Y; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Ishikura K; Ishiguro A; Ito S
    Pediatr Nephrol; 2024 Jun; 39(6):1825-1835. PubMed ID: 38270600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the time of initial relapse and subsequent relapses in patients with childhood-onset idiopathic nephrotic syndrome.
    Inoki Y; Nishi K; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Kamei K
    Pediatr Nephrol; 2024 Aug; 39(8):2393-2401. PubMed ID: 38267591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
    Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
    Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic rituximab administration in children with complicated nephrotic syndrome.
    Okutsu M; Kamei K; Sato M; Kanamori T; Nishi K; Ishiwa S; Ogura M; Sako M; Ito S; Ishikura K
    Pediatr Nephrol; 2021 Mar; 36(3):611-619. PubMed ID: 32995922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for nephrotic syndrome in children.
    Iijima K; Sako M; Nozu K
    Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
    Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
    Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
    BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
    Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
    J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
    Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
    J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
    Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
    Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
    Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome.
    Gbadegesin R; Hinkes B; Vlangos C; Mucha B; Liu J; Hopcian J; Hildebrandt F
    Pediatr Nephrol; 2007 Apr; 22(4):509-13. PubMed ID: 17216259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.
    Chan EY; Webb H; Yu E; Ghiggeri GM; Kemper MJ; Ma AL; Yamamura T; Sinha A; Bagga A; Hogan J; Dossier C; Vivarelli M; Liu ID; Kamei K; Ishikura K; Saini P; Tullus K
    Kidney Int; 2020 Feb; 97(2):393-401. PubMed ID: 31874801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.